Damora Therapeutics (DMRA) Profit After Tax (2019 - 2026)

Damora Therapeutics has reported Profit After Tax for 8 years, with the latest figure at -$27.8 million in Q1 2026.

• For the quarter ending Q1 2026, Profit After Tax fell 996.84% year-over-year to -$27.8 million; the trailing twelve-month figure through Mar 2026 stood at -$235.1 million (down 1171.09% YoY), and the FY2025 full-year result was -$209.8 million, down 878.77% from the prior year.
• Profit After Tax for Q1 2026 stood at -$27.8 million, up from -$200.7 million in the prior quarter.
• The five-year high for Profit After Tax was -$2.5 million in Q1 2025, with the low at -$200.7 million in Q4 2025.
• Historically, Profit After Tax has averaged -$21.1 million across 5 years, with a median of -$8.1 million in 2023.
• Annual changes were most pronounced in 2024 — Profit After Tax jumped 57.85% — and 2025, when it slumped 2877.84%.
• Damora Therapeutics' Profit After Tax stood at -$14.1 million in 2022, then surged by 53.98% to -$6.5 million in 2023, then retreated by 4.11% to -$6.7 million in 2024, then tumbled by 2877.84% to -$200.7 million in 2025, then soared by 86.16% to -$27.8 million in 2026.
• The last three Profit After Tax figures came in at -$27.8 million (Q1 2026), -$200.7 million (Q4 2025), and -$3.1 million (Q3 2025), per Business Quant data.